STING1 and melanoma: For instance, preclinical studies using subcutaneous B16 or B16F-10 melanoma models describe the induction of TLS following therapies aimed to improve DC function, including artificial adjuvant vector cells (aAVCs) (63), STING adjuvants (64) and oncolytic adenoviruses carrying IL-15 (Ad-IL15) (65).